ONESOURCE2026-08-31ONESOURCE2026-08-312026-08-31ResolutionOrAgendaDomain1ONESOURCE2026-08-31ResolutionOrAgendaDomain1ONESOURCE2026-08-312026-08-31ResolutionOrAgendaDomain2ONESOURCE2026-08-31ResolutionOrAgendaDomain2ONESOURCE2026-08-312026-08-31ResolutionOrAgendaDomain3ONESOURCE2026-08-31ResolutionOrAgendaDomain3ONESOURCE2026-08-312026-08-31ResolutionOrAgendaDomain4ONESOURCE2026-08-31ResolutionOrAgendaDomain4ONESOURCE2026-08-312026-08-31ResolutionOrAgendaDomain5ONESOURCE2026-08-31ResolutionOrAgendaDomain5ONESOURCE2026-08-312026-08-31ResolutionOrAgendaDomain6ONESOURCE2026-08-31ResolutionOrAgendaDomain6ONESOURCE2026-08-312026-08-31ResolutionOrAgendaDomain7ONESOURCE2026-08-31ResolutionOrAgendaDomain7xbrli:pureONESOURCEONESOURCE SPECIALTY PHARMA LIMITEDNew2026-09-2317:00:002026-08-31Annual General MeetingVideo Conference (VC) or Other Audio-Visual Means (OAVM)19th Annual General MeetingWednesday2026-09-2317:00:00Registered office7Ordinary ResolutionAdoption of Financial StatementsTo consider and adopt the audited financial statements (including the consolidated financial statements) of the Company for the financial year ended March 31, 2026 and the reports of the Board of Directors (“the Board”) and auditors thereonOrdinary ResolutionOthersOthersRetirement by RotationNeeraj Sharma is the Managing Director and was appointed effective March 01, 2024. Pursuant to Section 152 of the Companies Act, 2013, Neeraj Sharma retires by rotation and being eligible, offers himself for re-appointment as a Director of the Company. Relevant details of Neeraj Sharma pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standards on General Meetings issued by the Institute of Company Secretaries of India (ICSI) is enclosed as an Annexure 1 to this Notice. To consider and if thought fit, to pass the following resolution as an Ordinary Resolution: “RESOLVED that pursuant to the provisions of section 152 of the Companies Act, 2013 and rules made thereunder (including any statutory modification and re-enactment thereof and other applicable provisions, if any of the Companies Act, 2013, Neerj Sharma (DIN: 09402652) who retires by rotation and being eligible has offered himself for re-appointment, be and is hereby re-appointed as a Director of the Company, liable to retire by rotation.”Ordinary ResolutionOthersOthersAppointment of Statutory Auditors“RESOLVED that pursuant to the provisions of Sections 139, 142, and other applicable provisions, if any, of the Companies Act, 2013, read with the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), and based on the recommendation of the Audit Committee and the Board of Directors, M/s. B S R & Co LLP, Chartered Accountants (Firm Registration No.: 101248W/W-100022), be and are hereby appointed as the Statutory Auditors of the Company, to hold office for a period of 5 (five) consecutive years from the conclusion of the 19th Annual General Meeting until the conclusion of the 24th Annual General Meeting of the Company, at such remuneration as may be mutually agreed upon between the Board of Directors of the Company and the Statutory Auditors. RESOLVED FURTHER that the Board of Directors of the Company (which expression shall include any Committee thereof or person(s) authorised by the Board) be and are hereby authorised to do all such acts, deeds, matters and things as may be deemed necessary and/or expedient in connection therewith or incidental thereto, to give effect to the foregoing resolution.Special ResolutionOthersOthersAdditional Remuneration payable to Neeraj Sharma (DIN: 09402652), Managing Director for financial year ended March 31, 2026“RESOLVED that pursuant to Sections 197, 198 and other applicable provisions, if any, of the Companies Act, 2013, (the ‘Act’) read with Schedule V of the Act and the Rules made thereunder, and applicable provisions, if any, of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including any amendment(s), modification(s) or re-enactment(s) thereof for the time being in force, pursuant to the Articles of Association of the Company and in continuation to the resolution passed by the Members through postal ballot on July 30, 2025, on the recommendation of the Nomination and Remuneration Committee and as approved by the Board, approval of the Members of the Company be and is hereby accorded for the payment of additional remuneration of INR. 10 million (Indian Rupees Ten Million Only) to Neeraj Sharma (DIN: 09402652), Managing Director of the Company, for the financial year ended March 31, 2026. RESOLVED FURTHER that all other terms and conditions of appointment and remuneration of Neeraj Sharma, as approved by the Members through postal ballot on July 30, 2025 shall remain the same. RESOLVED FURTHER that any Director, Anurag Bhagania, Chief Financial Officer and Trisha A, Company Secretary & Compliance Officer of the Company, be and are hereby severally authorised to do all such acts, deeds, matters and things as may be deemed necessary to give effect to this resolution.”Special ResolutionOthersOthersCommission payable to Non-Executive Independent Directors of the Company“RESOLVED that pursuant to the provisions of Sections 149, 197, 198 and other applicable provisions, if any, of the Companies Act, 2013 read with Schedule V thereto, the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, Regulation 17(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, including any statutory amendment(s), modification(s), re-enactment(s) or substitution(s) thereof for the time being in force, the Articles of Association of the Company and pursuant to the recommendation of the Nomination and Remuneration Committee and the approval of the Board of Directors at their respective meetings held on July 24, 2026, and subject to such other approvals, permissions and sanctions, if any, as may be required, the approval of the Members of the Company be and is hereby accorded for payment of remuneration by way of commission, to each Non-Executive Independent Director of the Company, provided that the aggregate remuneration, including sitting fees paid/payable for the relevant financial year shall not exceed ₹ equivalent of €80,000 (Euro Eighty Thousand Only) per annum, with effect from FY 2025-26, for a period of 3 (three) years. RESOLVED FURTHER that the commission payable to each Non-Executive Independent Director shall be arrived at after adjusting the sitting fees paid during the relevant financial year. RESOLVED FURTHER that in the event of absence or inadequacy of profits in any financial year, the Non-Executive Independent Directors shall be eligible for the aforesaid commission. RESOLVED FURTHER that the Non-Executive Independent Directors shall also be eligible for travel, stay and other incidental expenses incurred by them in connection with the performance of their roles and duties. RESOLVED FURTHER that the Board (which expression shall include any Committee thereof), Anurag Bhagania, the Chief Financial Officer of the Company and/or such other person(s) authorized by the Board be and are hereby authorised to do all such acts, deeds, matters and things including deciding on the manner of payment of commission and settle all questions or difficulties that may arise with regard to the aforesaid resolution as it may deem fit and to execute any agreements, documents, instructions, etc. as may be necessary or desirable in connection with or incidental to give effect to the aforesaid resolution.”Ordinary ResolutionOthersOthersApproval of material related party transactions (RPTs) of the Company with Strides Pharma Science Limited“RESOLVED that pursuant to the provisions of Sections 177, 188 and other applicable provisions, if any, of the Companies Act, 2013 read with the Rules made there under and the Regulation 23(4) and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“the Listing Regulations”) including any statutory modification(s) or re-enactment(s) thereof for the time being in force read with SEBI Master Circular dated July 11, 2023 (last updated on January 30, 2026) and the Company’s Policy on materiality and dealing with related party transactions and in accordance with the omnibus approval and recommendation of the Audit Committee and the Board, and subject to such other approvals as may be necessary, the approval of the Members be and is hereby accorded to the company for entering into and/or continue the material related party transaction(s) with Strides Pharma Science Limited (Strides, India), whether individually or taken together with previous transactions during the financial year 2026-27, which are in the ordinary course of business and on arm’s length basis, and which may exceed 10% of the consolidated turnover of the Company, provided that the total value of such transaction(s) shall not exceed INR 3,201 million (~USD 35.6 million) during the said financial year. RESOLVED FURTHER that all the related parties to the said transaction shall be abstained from voting on this resolution in accordance with the applicable laws and regulations. RESOLVED FURTHER that the Board of Directors of the Company (which expression shall include any Committee thereof or person(s) authorized by the Board) be and is hereby authorized to do all such acts, deeds, matters and things and execute all such documents, undertakings and writings as may be necessary, desirable, or expedient to give effect to this resolution, including settling any questions or difficulties that may arise in this regard.”Ordinary ResolutionOthersOthersApproval of material related party transactions (RPTs) of the Company with Strides Pharma Inc, USA, (Wholly owned subsidiary (WOS) of Strides Pharma Science Limited)“RESOLVED that pursuant to the provisions of Sections 177, 188 and other applicable provisions, if any, of the Companies Act, 2013 read with the Rules made there under and the Regulation 23(4) and other applicable provisions of the 402 OneSource Specialty Pharma Limited Notice Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“the Listing Regulations”) including any statutory modification(s) or re-enactment(s) thereof for the time being in force) read with SEBI Master Circular dated July 11, 2023 (last updated on January 30, 2026) and the Company’s Policy on materiality and dealing with related party transactions and in accordance with the omnibus approval and recommendation of the Audit Committee and the Board, and subject to such other approvals as may be necessary, the approval of the Members be and is hereby accorded to the company for entering into and/or continue the material related party transaction(s) with Strides Pharma Inc., USA (Strides, USA), whether individually or taken together with previous transactions during the financial year 2026-27, which are in the ordinary course of business and on arm’s length basis, and which may exceed 10% of the consolidated turnover of the Company, provided that the total value of such transaction(s) shall not exceed INR 5,663 million (~USD 62.92 million) during the said financial year.RESOLVED FURTHER that all the related parties to the said transaction shall be abstained from voting on this resolution in accordance with the applicable laws and regulations. RESOLVED FURTHER that the Board of Directors of the Company (which expression shall include any Committee thereof or person(s) authorized by the Board) be and is hereby authorized to do all such acts, deeds, matters and things and execute all such documents, undertakings and writings as may be necessary, desirable, or expedient to give effect to this resolution, including settling any questions or difficulties that may arise in this regard.